Emerging therapies like complement and FcRn inhibitors are reshaping Myasthenia Gravis care, offering more targeted and effective options for patients. But with challenges in diagnosis, access, and long-term safety still in play, the road ahead demands innovation, collaboration, and a patient-centered approach.
